These novel therapies , Tirzepatide , represent a remarkable advancement in managing type 2 diabetes and possibly associated ailments . They all are classified as GLP-1 pathway activators , meaning https://cyrusabhk142228.answerblogs.com/41777392/semaglutide-a-comprehensive-exploration-into-glp-1-agents